NCT03600350 2025-05-09
pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
University of Wisconsin, Madison
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT00274287 2019-03-28
GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere
Oncology Specialists, S.C.
Phase 2 Completed
NCT00450463 2018-11-29
Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00400517 2018-08-28
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
The Cleveland Clinic
Phase 2 Completed
NCT00477087 2017-11-29
Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer
Stanford University
Phase 2 Terminated
NCT00450619 2017-01-04
153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00108732 2015-06-30
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00908141 2013-08-23
GM-CSF in Treating Patients With Relapsed Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00939510 2013-01-31
Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed